Physician profile
James Temprano
NPI 1093729972
$1,528.72
in general payments reported to CMS, 2019-2025
12 companies · $753 in 2025
The $753 reported for 2025 was more than what a typical Allergy & Immunology (Internal Medicine) provider received nationally (typical 2025 total: $681).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $17.12 · 2023: $162 · 2024: $597 · 2025: $753.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,512.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,511.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $444.57 | 2023-2025 | Fasenra, Airsupra, Evusheld |
| Genzyme Corporation | $238.79 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $176.38 | 2022-2025 | Cuvitru, Hyqvia, Eohilia |
| Ars Pharmaceuticals Operations, INC. | $147.98 | 2025 | Neffy |
| Novartis Pharmaceuticals Corporation | $124.98 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $121.61 | 2024 | Dupixent |
| Organon LLC | $109.18 | 2025 | Vtama |
| Glaxosmithkline, LLC. | $60.76 | 2023-2024 | Nucala |
| Pfizer INC. | $47.56 | 2023-2025 | |
| Amgen INC. | $20.35 | 2024 | Tezspire |
| Csl Behring | $19.78 | 2024 | Haegarda |
| Hospira, INC. | $16.78 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Temprano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.